2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5881 Bridging radiotherapy reduces systemic inflammation prior to CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphoma

Roshal R. Patel, MD, Sarah Samorodnitsky, PhD2, Sandeep Sunder Raj, MD3, Alessandro Criscimanna, MD4, Candela Ceballos5, Silvia Escribano Serrat, MD6, Marina Gomez-Llobell, MD7, Gunjan L. Shah, MD, MS8, Burcin Ucpinar9, Heiko Schoder, MD10, Mohammad Alhomoud, MD11, Parastoo B. Dahi, MD12, Richard J. Lin, MD, PhD13, Jae H Park, MD14, Craig Sauter, MD15, Michael Scordo, MD16, Gustav Cederquist, MD, PhD17, Zachary R. Moore, MD, PhD18, Gilles Salles I, MD, PhD19, Maria Lia Palomba, MD20, Joachim Yahalom, MD21, Miguel-Angel Perales, MD22, Roni Shouval Jr, MD, PhD23, Brandon S. Imber, MD, MA24
1 Memorial Sloan Kettering Cancer Center, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York, United States
23 Memorial Sloan Kettering Cancer Center, New York, United States
24 Memorial Sloan Kettering Cancer Center, New York, United States

Introduction: Systemic inflammation is increasingly recognized as a contributor to Chimeric Antigen Receptor T-cell therapy (CAR-T) failure in large B-cell lymphoma (LBCL) and represents a potentially modifiable pre-infusion state. Although bridging therapy may reduce inflammation through cytoreduction, radiotherapy (RT) can acutely cause local inflammation, raising concern that it may also increase systemic inflammation. We examined how bridging modality affects systemic inflammation and tumor volume before lymphodepletion (LD) and whether these changes are associated with CAR-T outcomes.

Methods: Patients with LBCL treated with CD19 CAR-T and evaluable inflammatory classification at leukapheresis and before lymphodepletion (LD) were included. INFLAMIX, a validated multicytokine serum signature that integrates circulating inflammatory mediators (Raj et al, Nature Med 2025), was used to classify patients as “inflammatory” or “non-inflammatory” at both timepoints. Bridging therapy was categorized as RT-containing (with or without systemic therapy) or as systemic therapy (ST) alone. Associations between bridging modality, longitudinal INFLAMIX classification and dynamics, and change in metabolic tumor volume (MTV) were assessed using Fisher’s exact test. Progression-free survival (PFS) and overall survival (OS) were estimated from CAR-T infusion using the Kaplan-Meier method and compared using the log-rank test.

Results: Among 421 analyzed patients, 59% were bridged with ST alone, 16% with RT alone, 6% with combined ST+RT, and 18% had no bridging therapy. Baseline pre-apheresis disease burden was comparable between patients receiving RT-containing bridging and systemic therapy (ST) alone regimens, including leukapheresis MTV (P=0.4), LDH (P=0.8), and presence of bulky disease ≥7.5 cm (P=0.6). Patients bridged with RT-containing regimens had less stage III/IV disease (62% vs 77%; P<0.001).

Overall, the proportion of patients with elevated inflammatory state decreased from 44% at leukapheresis to 29% before LD. This reduction was greater for patients who received RT-containing bridging (41% pre-apheresis to 13% pre-LD) vs ST regimens (44% to 35%; P<0.001). Conversion from an inflammatory to a non-inflammatory state occurred in 33% of RT-bridged patients vs 19% after ST alone; persistently elevated inflammation remained in 8% after RT-bridging vs 25% after ST-bridging. Conversion from a non-inflammatory to an inflammatory state was rare after RT-containing bridging (4% vs 10% treated with ST). Quantifiable MTV reduction was more frequent among patients who converted from inflammatory to non-inflammatory than among those who remained or became inflammatory during the bridging period (86% vs 47%; P<0.001).

Achieving a non-inflammatory state before LD, irrespective of bridging strategy, was associated with superior PFS and OS regardless of inflammatory status at leukapheresis (both P<0.001). Patients who achieved both MTV reduction and a non-inflammatory state before LD had the most favorable PFS and OS (both P<0.001).

Conclusion: Challenging the longstanding assumption that RT exacerbates inflammation, bridging RT significantly reduced systemic inflammation, potentially through rapid and effective cytoreduction. RT-containing bridging regimens normalized inflammation more often than strategies containing ST alone. Because the pre-LD inflammatory state is both prognostic and modifiable, these findings support investigating INFLAMIX-guided CAR-T bridging decisions and expanding the role of bridging RT beyond local control. RT should be explored as a purposeful inflammatory modulator to optimize the pre-CAR-T microenvironment.

Brandon S. Imber, MD, MA: GT Medical Technologies, Inc - Honoraria; Kite Therapeutics - Honoraria; Kazia Therapeutics - Research Funding; GT Medical Technologies, Inc - Research Funding; Novartis - Research Funding; AstraZeneca - Research Funding; GT Medical Technologies, Inc - Consultancy (Includes expert testimony)